Clin Cancer Res: The effect of fulvestrant + everolimus + anastrozole in the first-line treatment of HR-positive advanced breast cancer

Metastatic hormone receptor positive (HR positive), HER2-negative breast cancer is an important cause of cancer-related deaths
.

For a long time, endocrine therapy with or without other targeted therapies has been the main treatment for this type of breast cancer

Breast cancer

This trial aims to evaluate the efficacy of fulvestrant combined with everolimus vs.
fulvestrant combined with everolimus and anastrozole as a first-line regimen for the treatment of HR-positive and HER2-negative advanced breast cancer
.

To evaluate the effect of fulvestrant combined with everolimus vs fulvestrant combined with everolimus and anastrozole as a first-line regimen for the treatment of HR-positive and HER2-negative advanced breast cancer

This is a randomized placebo-controlled clinical trial that recruits postmenopausal patients with HR-positive and HER2-negative advanced breast cancer who have not received systemic treatment in the past
.

The test patients were randomly divided into three groups and received fulvestrant + everolimus, fulvestrant + everolimus + anastrozole or fulvestrant monotherapy

Progression-free survival of each group

Progression-free survival of each group

From May 2014 to February 2015, partly due to changes in clinical practice, the study was stopped after only 37 patients were recruited
.

Compared with fulvestrant alone, there is no evidence that combination therapy containing everolimus can improve the progression-free survival or overall survival of such advanced breast cancer patients

Compared with fulvestrant alone, there is no evidence that combination therapy containing everolimus can improve the progression-free survival or overall survival of such advanced breast cancer patients

Overall survival of each group

Overall survival of each group

Among the 36 evaluable patients, no toxic reaction of grade 3 or higher occurred in the fulvex group
.

One patient in the fulvestrant combined with everolimus group had a grade 4 toxic reaction (hypophosphatemia).

All in all, although the scale of the study is limited, the results of the study do not support the routine use of everolimus combined with endocrine therapy in the first-line treatment of hormone-positive advanced breast cancer

The routine use of everolimus combined with endocrine therapy in the first-line treatment of hormone-positive advanced breast cancer does not support the routine use of everolimus combined with endocrine therapy in the first-line treatment of hormone-positive advanced breast cancer

Original source:

Original source:

Halle CF Moore, William E.

A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222 in this message